Phospho-EGF Receptor (Tyr1068) Recombinant Rabbit mAb (S-4267)

Phospho-EGF Receptor (Tyr1068) is one of the most critical autophosphorylation sites signifying EGFR tyrosine kinase activation. Its phosphorylation is strictly dependent on ligand-induced receptor dimerization and the subsequent conformational activation of the intracellular kinase domain. Upon phosphorylation, Tyr1068 functions as a high-affinity docking site that directly recruits the adaptor protein GRB2, thereby cascading downstream activation of the MAPK/ERK proliferative signaling and PI3K/AKT survival pathways via the SOS/RAS axis. This site exhibits precise functional with other C-terminal domain residues—Y1045 (c-Cbl binding mediating degradation), Y992 (PLCγ binding), and Y1173 (Shc scaffold binding)—with Y1068 being specifically dedicated to GRB2-mediated pro-proliferative signal input. Its phosphorylation level is subject to stringent subcellular spatial regulation: it is directly dephosphorylated at the plasma membrane by receptor-type phosphatases such as PTPRJ to limit signal intensity, and upon internalization to the endoplasmic reticulum, it is inactivated by PTPN2, forming a spatially dependent negative feedback braking mechanism. In terms of clinical translation, pY1068 has transcended its role as a classic marker of EGFR activation. Large-scale studies in advanced non-small cell lung cancer (NSCLC) have demonstrated that positivity for this phosphorylation site serves as an independent predictive biomarker for significant progression-free survival (PFS) benefit from gefitinib or erlotinib treatment in EGFR wild-type patients (median PFS 4.2 months vs. 1.2 months).